GlassScriptPhysician profile
Allison Carpio
NPI 1649688359
$1,602.79
in general payments reported to CMS, 2019-2025
20 companies · $703 in 2025
The $703 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.55 · 2024: $800 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $346.66 | 2024-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $250.87 | 2024-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $170.10 | 2024-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $119.79 | 2025 | |
| Mallinckrodt Hospital Products INC. | $107.22 | 2024-2025 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $92.06 | 2024-2025 | Lupkynis |
| Ardelyx, INC. | $78.04 | 2024 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $70.44 | 2024-2025 | Farxiga |
| Glaxosmithkline, LLC. | $68.37 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.22 | 2024-2025 | |
| Novo Nordisk INC | $42.68 | 2024 | Rybelsus, Ozempic |
| Alexion Pharmaceuticals, INC. | $33.18 | 2024-2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $31.18 | 2021 | |
| Ani Pharmaceuticals, INC. | $29.60 | 2025 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $21.98 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $20.32 | 2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.88 | 2024 | Jardiance |
| Amgen INC. | $17.09 | 2025 | Tavneos |
| Cvrx, INC. | $16.65 | 2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $14.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Carpio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.